Publish in this journal
Journal Information
Vol. 49. Num. 182.April - June 2014
Pages 31-66
Vol. 49. Num. 182.April - June 2014
Pages 31-66
The efficacy and safety of oral mucopolysaccharide, type I collagen and vitamin C treatment in tendinopathy patients
Visits
5511
Andreu Arquera, Miquel Garcíab, José Antonio Lauciricac, Marta Riusd, Marian Blàviae, Jaume Fontserèf, Carlos Hernándezg, Jordi Boludah, Tomislav Kranjceci, Ana de la Torrej, Gilberto Díazk, Karin Freitagl, José M. Villalónm, Jaime Baselgan, Pedro Hernándezn, José Gonzalezo, Guillermo Rodríguezo, Horacio Rodríguezp, Juan María Alarcónp, Carlos T. Simorteq, Isaac Vicenter, Montserrat Cabanasr, Pablo Ramírezr, Daniel Martínez Puigr
a Centre d’Alt Rendiment (CAR-GIRSANE), Sant Cugat del Vallès, Barcelona, España
b Clínica Teknon, Barcelona, España
c Artro Esport, Barcelona, España
d Mútua Catalana de Fútbol, Barcelona, España
e Clínica Diagonal, Esplugues de Llobregat, Barcelona, España
f Traumasalut, Sabadell, Barcelona, España
g Unitat de Medicina de l’Esport, Xarxa Sanitària i Social de Santa Tecla, Tarragona, España
h Lenox Corachan, Barcelona, España
i Activa Mútua, Clínica Diagonal y Centros, Barcelona, España
j Clínica CEMTRO, Madrid, España
k Clínica Asepeyo, Madrid, España
l Centro Integral del Aparato Locomotor, Madrid, España
m Hospital Universitario Montepríncipe, Madrid, España
n Hospital Ruber Internacional, Madrid, España
o Clínica DEYRE, Madrid, España
p Clínica Nuestra Señora de América, Madrid, España
q Hospital de Madrid, Madrid, España
r Bioibérica S.A., Palafolls, Barcelona, España
This item has received
5511
Visits
Article information
Introduction and objectives

Tendinopathy, which is accompanied by structural changes to the tendon, is a common sporting injury. The aim of this study was to evaluate the efficacy and safety of a nutritional supplement containing mucopolysaccharides, type I collagen and vitamin C (TendoactiveTM) on the clinical and structural evolution of tendinopathies of the Achilles tendon, patellar tendon and lateral epicondyle tendon in the elbow.

Materials and methods

A multicenter, open-label, non-comparative, prospective, exploratory phase iv study was performed. A total of 98 tendinopathy patients (32 Achilles, 32 patellar and 34 lateral epicondylar), who received a daily dose of 435 mg mucopolysaccharides, 75 mg type i collagen and 60 mg vitamin C (equivalent to three capsules of TendoactiveTM per day) for 90 consecutive days, were included. Every month, pain at rest and when active was assessed using a visual analogue scale (VAS), joint function was assessed using the VISA-A, VISA-P and PRTEE questionnaires, and the tendon affected was characterized by ultrasound.

Results

A significant reduction in pain both at rest and when active was observed between the first control visit (day 30) and the end of the study (day 90) for all three types of tendinopathy. Thus, a 38% improvement in VISA-A, 46% in VISA-P and 77% in PRTEE was observed on day 90 (P < .001). Similarly, a 12% decrease in the thickness of the Achilles tendon, a 10% decrease in the patellar tendon and a 20% decrease in the lateral epicondyle tendon was observed (P < .05).

Conclusions

The results of this study show that the administration of TendoactiveTM is safe and effective for improving the clinical symptoms and structural evolution of tendinopathies of the Achilles, patella and lateral epicondyle tendons.

Keywords:
Tendinopathy
Clinical trial
Diet supplement
Full text is only aviable in PDF
Apunts Medicina de l'Esport (English Edition)

Subscribe to our Newsletter

Article options
Tools
Cookies policy
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.